Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis
Desbois et al.,
Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with sarcoidosis,
Research Square, doi:10.21203/rs.3.rs-41653/v1 (Preprint)
Retrospective 199 sarcoidosis patients showing non-statistically significant HCQ RR 0.83, p=1.0.
risk of case, 16.9% lower, RR 0.83, p = 1.00, treatment 3 of 27 (11.1%), control 23 of 172 (13.4%), NNT 44.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Desbois et al., 20 Jul 2020, retrospective, France, preprint, mean age 58.8, 13 authors.
Abstract: Prevalence and clinical features of COVID-19 in a
large cohort of 199 patients with sarcoidosis
Anne-Claire Desbois
Hopital Universitaire Pitie Salpetriere
Cindy Marques ( cindymarques@ymail.com )
Hopital Universitaire Pitie Salpetriere https://orcid.org/0000-0002-1361-0575
Leila Lefèvre
Hopital Universitaire Pitie Salpetriere
Serge Barmo
Hopital Universitaire Pitie Salpetriere
Camille Lorenzo
Hopital Universitaire Pitie Salpetriere
Mathilde Leclercq
Hopital Universitaire Pitie Salpetriere
Gaëlle Leroux
Hopital Universitaire Pitie Salpetriere
Chloé Comarmond
Hopital Universitaire Pitie Salpetriere
Catherine Chapelon
Hopital Universitaire Pitie Salpetriere
Fanny Domont
Hopital Universitaire Pitie Salpetriere
Mathieu Vautier
Hopital Universitaire Pitie Salpetriere
David Saadoun
Hopital Universitaire Pitie Salpetriere
Patrice Cacoub
Hopital Universitaire Pitie Salpetriere
Research article
Keywords: sarcoidosis, COVID-19, SARS-CoV-2
Posted Date: July 20th, 2020
DOI: https://doi.org/10.21203/rs.3.rs-41653/v1
License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
1
Prevalence and clinical features of COVID-19 in a large cohort of 199 patients with
2
sarcoidosis
3
Anne-Claire Desbois*1,2,3, Cindy Marques*1,2,3, Leila Lefèvre2,3, Serge Barmo2,3, Camille
4
Lorenzo2,3, Mathilde Leclercq2,3, Gaëlle Leroux2,3, Chloé Comarmond1,2,3, Catherine
5
Chapelon-Abric2,3, Fanny Domont2,3, Mathieu Vauthier2,3, David Saadoun1,2,3, Patrice
6
Cacoub1,2,3
7
* equal contribution
8
9
1. Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-
10
Immunopathology- Immunotherapy (I3); F-75005, Paris, France;
11
2. Biotherapy (CIC-BTi) and Inflammation-Immunopathology-Biotherapy Department (DHU
12
i2B), Hôpital Pitié-Salpêtrière, AP-HP, F-75651, Paris, France;
13
3. AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical
14
Immunology, F-75013, Paris, France, Centre national de référence des Maladies
15
Autoimmunes et systémiques rares et Maladies Autoinflammatoires rares
16
17
Correspondence: Anne-Claire Desbois, MD, PhD, Department of Internal Medicine and
18
Clinical Immunology, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l’Hôpital, 75013 Paris.
19
Phone: + (33)(1) 42 17 80 68. Fax: + (33)(1) 42 17 80 33.
20
E Mail:anneclaire.desbois@aphp.fr
21
22
Conflict of interest: The authors have declared that no conflict of interest exists.
23
24
Word Count: 1496 words, 10 217 characters (including spaces), 2 tables, 20 references.
25
26
27
Declarations
28
The study was approved by our institutional ethics review board "Ethics committee of
29
research in Sorbonne University". All patients gave informed consent.
Ethics approval and consent to participate:
30
31
Consent for publication:
32
Not applicable.
33
34
Availability of data and materials:
35
The datasets used and/or analyzed during the current study are available from the
36
corresponding author on reasonable request.
37
38
Competing interests:
39
The authors declare that they have no competing interests.
40
41
Funding:
42
The authors declare that they have no source of funding.
43
44
Authors' contributions:
45
ACD contributed to the conception and design of the work.
46
ACD and CM wrote the manuscript.
47
ACD, CM, LL, SB, CL, ML, GL, CC, CCA, FD, MV and DS collected the data.
48
CM have drafted the work
49
PC supervised the..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit